XNAS
WINT
Market cap509kUSD
Jul 09, Last price
0.02USD
1D
-4.93%
1Q
-10.12%
Jan 2017
-100.00%
Name
Windtree Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.37%
Rev. gr., 5y
-27.38%
Revenues
0k
Net income
-5m
L-72.96%
CFO
-15m
L+14.62%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing innovative therapies for acute cardiovascular conditions. Its robust pipeline features several key therapeutic candidates at various clinical stages: Istaroxime, their flagship compound, is currently undergoing Phase 2b clinical trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Beyond cardiovascular indications, Windtree is advancing two surfactant-based therapies: AEROSURF, an aerosolized KL4 surfactant, is in Phase 2b for respiratory distress syndrome in premature infants. Surfaxin, a lyophilized KL4 surfactant, is in Phase 2a trials addressing lung injury associated with COVID-19. Rostafuroxin is another asset, currently in Phase 2b trials for genetically linked hypertension. Additionally, the company is exploring an oral and intravenous SERCA2a activator in preclinical studies, targeting both chronic and acute forms of heart failure. Windtree actively engages in strategic collaborations to bolster its research and development efforts. Partnerships include scientific cooperation with Chang Gung University focusing on cardiovascular aspects of SERCA2a, and a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds designed for chronic and acute human heart failure. Further alliances comprise a strategic partnership with Laboratorios del Dr. Esteve, S.A. for the global development, commercialization, and sales of its KL4 surfactant product portfolio, and an agreement with Battelle Memorial Institute specifically for the advancement of its ADS technology, crucial for their Phase III program. Tracing its origins back to 1992, the company initially operated as Discovery Laboratories, Inc. before rebranding as Windtree Therapeutics, Inc. in April 2016. Its corporate headquarters are situated in Warrington, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||